Proprietary Data Legend N/A A. IDENTIFICATION AND SIGNIFICANCE OF THE PROBLEM, AND TECHNICAL APPROACH
The overall goal of this project is development of a targeted radiotracer for PET imaging of the receptors for epidermal growth factor (EGFR) in cancer patients. The significance and the impact of such radiotracer is determined by the crucial role that EGFR plays in many cancers and by rapid entrance into the clinic of new drugs that target this receptor (Baselga & Arteaga, 2005) . Since only 10-25% of patients respond to these drugs, their rational use requires information on EGFR prevalence to enable 1) patient segmentation, 2) rapid monitoring of responses to therapy, and 3) development of new personalized treatment regimens. Currently, EGFR prevalence is evaluated by immunohistochemical analysis of tissue biopsies, which proved to be rather inefficient in predicting of treatment outcome (Scagliotti, et al., 2004; Chung et al., 2005; Bell et al., 2005) . Thus, EGFR imaging with targeted PET radiotracer holds the promise to satisfy unmet clinical needs.
In considering technical approach to development of such radiotracers we decided that using EGF, a natural ligand for EGFR, as a targeting vector might be particularly advantageous. First, EGF binds to EGFR with high affinity and is internalized via receptor-mediated endocytosis, providing for intracellular accumulation of radionuclide. Second, small size of mature EGF would facilitate tumor penetration. Third, as a human protein, EGF is not expected to be immunogenic. Finally, we have recently engineered and expressed functionally active EGF with an N-terminal tag for site-specific conjugation (Cys-tag), derivatized this protein with fluorescent dye Cy5.5 for near-infrared fluorescent imaging, and established that EGF-based contrast agent is functionally active, images tumors in mouse models and accumulates in tumor cells in vivo (Backer et al., 2007) . Taken together, these argue in favor of using EGF as a targeting vector. As possible disadvantage of using EGF, we consider concerns about potential physiological effects of EGF-based tracers. Although a definitive answer to these concerns requires extensive experimentation, we expect that injection of small amounts of EGF for diagnostic imaging will cause no adverse effects.
For radiolabeling of Cys-tagged EGF we propose to use 64 Cu. This selection is based on the following chemical and logistical advantages. First, there is no need for radiochemical synthesis, because radiolabeling with 64 Cu needs only a chelator, which is conjugated to the protein via "cold" chemistry. A functionalized macrocyclic chelator DOTA suitable for conjugation is available commercially. In our experience, site-specific conjugation of DOTA to Cys-tagged protein via a pegylated linker does not affect activity of the protein and favorably modify clearance and biodistribution of the resulting 64 Cu radiotracer. Second, radiolabeling of protein-chelator conjugate with 64 Cu requires only a short incubation followed by purification on a desalting column, which can be done by the end-user immediately before imaging. Third, reasonably high 64 Cu stability (t 1/2 = 12.7 h) allows imaging several hrs after injection of the tracer, thereby improving signal-to-background ratio due to clearance of free and nonspecifically bound tracer. Finally, using a similar strategy (site-specific conjugation of DOTA to Cys-tagged protein via a pegylated linker), we are currently developing 64 Cu PET radiotracer for imaging receptors for vascular endothelial growth factor in tumor angiogenesis (Backer et al., 2007) . This experience, as well as established collaboration with Dr. F. Blankenberg (Stanford University), are fully translatable to this project.
Topic 51/a1. Development of Cu-64 labeled EGF for In Vivo PET Imaging of EGFR Expression SibTech, Inc. Award # Guided by the significance of the problem and selected technical approach, in Phase I of this project we propose to prepare EGF-based 64 Cu PET radiotracer and validate it in mouse tumor model. Accomplishing specific technical objectives with quantitative milestones will allow us to proceed with clinical development of this radiotracer in Phase II and III of the project.
B. ANTICIPATED PUBLIC BENEFITS
We expect that the end-result of this project will be EGF-based 64 Cu PET radiotracer approved for clinical use in cancer patients. Molecular imaging of EGF receptors will be a dramatic step to personalized medicine, because it will provide direct information on the prevalence of the drug target and responses to therapy for individual patients. Considering staggering cost of EGFR-targeted therapeutics and positive response only in 10-25% of patients, advances in patient segmentation and monitoring will benefit patient population and will significantly decrease a healthcare cost for the society. Providing targeted PET radiotracer also makes economic sense, as seen from the following estimations. A current price of a contrast agent for PET imaging is ~$500/imaging and it is a relatively small fraction of the overall cost of PET imaging ($3,000-6,000). It is estimated that by 2010, in excess of 2,000,000 PET scans will be performed per year. If a price of a targeted contrast agent will be within $500-1000 range and only 1% of PET scans will be performed with EGF-based PET 64 Cu radiotracer, the market size for this tracer might reach $10-20 millions/year. Cys-tagged EGF and dEGF. To make site-specifically radiolabeled tracers, we use EGF expressed with N-terminal Cys-tag ( Fig. 2) , 15-aa fusion tag containing a cysteine residue (C4) for site-specific conjugation of various payloads (described in Backer et al., 2007 ; Cys-tag is reviewed in Backer et al., 2008) . Since proper EGFR activity requires dimerization and interaction with two EGF molecules, we considered a possibility that it might be difficult to accommodate two EGF-PEG-DOTA conjugates in such complex. To circumvent this potential problem we engineered a head-to-tail EGF dimer (dEGF) with one Cys-tag (Fig. 2) . EGF and dEGF were expressed in E.coli, recovered from inclusion bodies, refolded in red-ox buffer containing glutathione, and purified via ion-exchange chromatography (Backer et al., 2007) . As other Cys-tagged proteins refolded in red-ox buffer, EGF and dEGF proteins are recovered with C4-thiol group in Cys-tag "protected" in a form of a mixed disulfide with glutathione.
C. DEGREE TO WHICH PHASE I HAS DEMONSTRATED TECHNICAL FEASIBILITY
Conjugate synthesis. PEG-DOTA was conjugated to EGF and to dEGF through the following two-step procedure (Fig. 3a) .
Step 1. Activated DOTA is prepared by derivatization of p-NH 2 -Bn-DOTA (2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (Macrocyclics, Dallas, TX) with 5 kDa NHS-PEG-MAL, polyethylenglycol (PEG) with amino-reactive NHS group on the one end and thiol-reactive maleimide on the other end of each PEG molecule (NOF America, Terrytown, NY). Activation is performed at 2:1 molar ratio of DOTA to PEG in a buffer containing 15 mM NaOAc, 50 mM Na 2 CO 3 , 115 mM NaCl, pH 8.0. Reaction is stopped by addition of 1 M Tris HCl pH 8.0 to a final concentration of 100 mM, and incubated for 30 min to hydrolyze unreacted NHS. DOTA-PEG-Mal is stored at -70 o C in small aliquots. ) and over-modified (<10%) EGF by RP-HPLC. Second peak (shown in pink) was collected; buffer-exchanged on PD-10 column, and concentrated to concentration ready for radionuclide loading (1-2 mg/ml). C, samples of unmodified proteins (lanes 1), modification reaction mixtures (lanes 2) and RP-HPLCpurified products (lanes 3) were analyzed by reducing SDS-PAGE on 20% gels. PL, protein ladder (BioRad). Molecular weights are indicated in kDa. Single or doubled copy of human EGF was cloned in-frame with N-terminal Cys-tag (Backer et al., 2007 (Backer et al., , 2008 . Both proteins were expressed in E.coli, refolded into functionally active conformations in red-ox buffers and purified via ion-exchange chromatography.
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Step 2. "Deprotected" EGF (or dEGF) is freshly prepared by incubating EGF with equimolar amount of DTT for 30 min at room temperature, in order to release C4-thiol group from mixed disulfide with glutathione (Backer et al., 2007) . DOTA-PEG-Mal conjugate is then added to deprotected protein at the Mal-to-protein ratio of 2:1 and incubated for 1 h at room temperature. The reaction mixture is passed through PD-10 and then fractionated on C4 RP-HPLC, which provides for good separation of unmodified protein and EGF-PEG or dEGF-PEG-DOTA conjugates (Fig. 3b, for EGF) . RP-HPLC purification is followed by solvent exchange on PD10 into buffer containing 0.1 M NaOAc pH 5.5. Final preparations are obtained by concentration of purified conjugates via reverse dialysis using Aquacide III powder (Calbiochem) and stored at -70 o C in small aliquots. As judged by SDS-PAGE, the final preparations contained less then 5% of unmodified protein (Fig. 3c , lanes #3 for EGF and dEGF).
Conjugate activity. Functional activities of EGF-based conjugates are tested in two cell culture based assays. In a short-term assay (10 min), conjugates are tested for the ability to bind to EGFR and induce its tyrosine phosphorylation. In this assay EGF-PEG-DOTA and dEGF-PEG-DOTA displayed similar dose-dependences as parental proteins (Fig. 4a) .
In a long-term competition assay (3 days), conjugates are tested for their ability to protect EGFR-positive cells from EGF-based cytotoxin. We reasoned that in this assay binding of EGFbased construct to EGFR reaches equilibrium and eliminates any kinetic effects that might affect binding in a short-term assay. We found that in this assay both EGF-PEG-DOTA and dEGF-PEG-DOTA displayed activity very similar to that of parental proteins (Fig. 4b) .
Since loading DOTA chelator with radionuclides takes place at elevated temperature, we also tested how it might affect its functional activity. We found that incubation of EGF-PEG-DOTA conjugates in radiolabeling buffer at 95 o C for 30 min does not decrease its functional activity (Fig. 4b) . 
Radiolabeling of conjugates with
64 Cu. The 64 Cu radiolabeling protocol was initially developed for scVEGF-PEG-DOTA conjugates (Backer et al., 2007) and it was further optimized as described in details elsewhere (Backer et al., 2008) . Briefly, the current protocol is as follows:
Topic Mouse tumor model. Two mouse models were used in these experiments, 1) F98/EGFR rat glioma (~10 6 EGFR/cell), grown subcutaneously, and 2) luciferase-expressing MDA231luc human breast carcinoma (~2x10 5 EGFR/cell), grown orthotopically. 4.5 mln F98/EGFR cells/mouse were injected subcutaneously on the back of 5-6 week old female SCID/NCr (BALB/c background) mice (Charles River Laboratories, Wilmington, MA). 3 mln MDA231luc cells/mouse were injected into the left axillary fat pad of SCID/NCr (BALB/c background) mice. The protocols for all animal studies were approved by the Stanford University Institutional Animal Care and Use Committee and by University of Connecticut Health Center Animal Care and Use Committee Biodistribution. For biodistribution and imaging studies, 95 Ci of either EGF-PEG-DOTA/ 64 Cu or dEGF-PEG-DOTA/ 64 Cu were intravenously injected into mice (n=4) 9 days after tumor cell implantation. An early time point, when tumors were just palpable (3-5 mm) was selected in order to establish if EGF-based tracers are suitable for early tumor detection. Mice were imaged at 3-4 hours post-injection, and then sacrificed at 22 hours post-injection for biodistribution studies. For biodistribution, blood was collected, organs were harvested, weighed, and counted in a gamma counter with the exception of carcass, which was placed in a glove and counted and normalized to a full dose of injected activity in a dosimetric calibrator. Results were expressed as both % injected dose (ID) and % ID per gram. Accounting for natural decay of 64 Cu (t 1/2 =12.7 h) was incorporated into calculations. The data are presented in Fig. 5 as %ID/g and compared with several protein-based 64 Cu PET tracers in Table 1 .
The major uptake organs, were liver, kidney, and spleen. In all organs, the uptake of the dEGF-based tracer was >3-fold lower than for EGF-based tracer. The tumor uptake in F98/EGFR and MDA231luc tumors was, respectively, 1% and 1.7 %ID/g for EGF-based tracer and 0.3 and 0.3 %ID/g for dEGF-based tracer. Thus, unfortunately, the lower uptake of dEGFbased tracer was observed not only in major organs, but also in tumors. Interestingly, both tracers, the uptake in F98/EGFR tumors was somewhat lower than in MDA231luc, despite the Topic 51/a1. Development of Cu-64 labeled EGF for In Vivo PET Imaging of EGFR Expression SibTech, Inc. Award # fact that the latter cells express ~5-fold less EGFR in tissue culture. We found this result very instructive, since it indicates that only functional in vivo tests can provide meaningful information about receptor activity in vivo.
It should be pointed out that at 22-hour post-injection, the uptake in both tumors was still 5-10 times higher that in muscle tissue, providing excellent opportunity for imaging. Topic 51/a1. Development of Cu-64 labeled EGF for In Vivo PET Imaging of EGFR Expression SibTech, Inc. Award # DE-FG02-07ER84905
Our goal in this Technical Objective was to establish feasibility of imaging with EGFbased tracers. In these experiments we used the same tumor models, described in Technical Objective #2. Mice with very small tumors (2-5 mm) were imaged 3-4 hours post-injection. Tumor presence was validated by bioluminescent imaging after intraperitoneal luciferine injection, as described elsewhere (Backer et al., 2007) . A typical set of PET images obtained with EGF-PET-DOTA/ 64 Cu and dEGF-PET-DOTA/
64
Cu in MDA231luc tumor-bearing mice is shown in Fig. 6 . The key finding is that tumors (white arrowheads) as small as few millimeters can be detected with both tracers. Similar results were obtained with subcutaneous F98/EGFR tumors.
. Two additional tasks were planned for this part of the project. One task was to develop a tracer based on inactivated EGF-PEG-DOTA. Based on our experience with other growth factors, we expected to make inactivated EGF tracers by excessive biotinylation of amino groups. This approach did not work with EGF-based tracers, because biotinylated EGF retained full functional activity. We are now exploring a possibility of development of inactivated tracers based on mutant EGF, which does not bind to the receptor.
The other task was to use siRNA to alter EGFR expression. We decided against using this approach because recent findings indicated that siRNA can alter cell physiology through Tolllike receptor mediated mechanism(s), rather than via expected specific mechanisms (Kleinman et al., 2008) . This would complicate interpretation of imaging data and, if pursued, would take us away from the focus on development of the tracers.
Summary for Technical Objective #3. The main task of this technical objective is achieved. We established that EGF-and dEGF-based PET tracers can be used for imaging of very small (3-5 mm) tumors. The auxiliary task was not undertaken for scientific reasons. Topic 51/a1. Development of Cu-64 labeled EGF for In Vivo PET Imaging of EGFR Expression SibTech, Inc. Award # DE-FG02-07ER84905
Technical
As described in the Section A. Identification and Significance of the Problem, in the course of the work on this project we discovered that thiol group in Cys-tag can be directly radiolabeled with [ 99m Tc]pertechnate, yielding stable and efficient SPECT tracers (Levashova et al., 2008; Backer et al., 2008) . We therefore extended our project to establish feasibility of developing EGF-based tracer for SPECT imaging. EGF and dEGF were directly radiolabeled with [ 99m Tc]pertechnate and the resulting EGF/Tc and dEGF/Tc tracers were explored as imaging agents.
We found that these tracers bind to F98/EGFR cells with expected Kd and N (Fig. 7A) , as judged by Scatchard's analysis (Fig. 7A for EGF Scatchard's analysis was undertaken with F98/EGFR cells, using protocol described elsewhere (Backer et al., 2007 , Levashova et al., 2008 . Non-specific binding was determined upon addition of 200-fold excess of cold EGF. B, For stability experiments two Balb/c mice were injected i.v. with a tracer (55 μCi/0.25 μg per mouse) and sacrificed 2 min later. Blood was collected and clarified by centrifugation. Plasma samples were incubated at 37 o C. After 0, 10, 30, and 60 min of incubation, 1-μL plasma aliquots were analyzed by ITLC to determine the protein-bound radioactivity. C, For clearance experiments 55 μCi of tracer/mouse (n=4) was injected via the tail vein and serial ~50-µL blood samples were taken via supraorbital sinus at various time points after injection and counted in a gamma counter along with three samples of standard activity (1/100 of injected dose). Results were calculated as the average of the percentage of injected dose per gram (%ID / g) of blood sample ± one STD of the mean.
Biodistribution experiments were performed on MDA231luc tumor-bearing mice with well-formed tumors at 25-day post implantation. Biodistribution data in %ID/g for both EGF/Tc and dEGF/Tc are shown in Fig. 8 , and comparison with other proteins in Table 2 . We found that dEGF/Tc uptake was higher in kidney and liver, but lower in small and large bowel. Interestingly, uptake in tumor was higher for dEGF/Tc tracer and there were no significant difference between the edge and the center of the tumor. SPECT tracers were tested in two tumor models: orthotopic MDA231luc breast carcinoma and spontaneous mouse lung carcinoma that arise in bi-transgenic mice (FVBN original strain carrying myc or ras transgenes regulated by a tetracycline-inducible lung-specific promoter. In both models, tracers readily accumulated in tumors (Fig. 9) . 
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To further explore distribution of tracer, after imaging with EGF-based 99m Tc tracers, we have selected two EGF/Tc-injected mice with MDA231luc tumors, harvested tumors, prepared cryosections, and undertook autoradiography of the sections. Cryosections prepared from contralateral muscle were used as control. As shown in Fig. 10A , radioactivity was significantly higher in tumor cryosections, as compared with muscle cryosections.
In a similar experiment, we selected a bi-transgenic mouse in which SPECT with dEGF/ 99m Tc-detected tumor only in the left lung, harvested and cryosection both lungs, and undertook autoradiography of cryosections. As shown in Fig. 10B , radioactivity was significantly higher in left lung cryosections, as compare with the right lung. 
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